



INFORMATION DISCLOSURE CITATION <small>1 FEB 12 2007</small>	Docket No.: RLL-290US		Serial No.: 10/552,502
	Applicants: MEHTA et al.		
	Filed: 10/7/2005	Group: Art Unit 1626	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JN/	A1	3,176,019	3/30/1965	Campbell et al.	260	293.4	
/JN/	A2	5,281,601	1/25/1994	Cross et al.	514	320	
/JN/	A3	5,948,792	9/7/1999	Tsuchiya et al.	514	317	
/JN/	A4	6,034,082	3/7/2000	MacKenzie et al.	514	233.5	
/JN/	A5	6,130,232	10/10/2000	Mase et al.	514	318	
/JN/	A6	6,174,900	1/16/2001	Okada et al.	514	317	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
/JN/	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54	<input type="checkbox"/>
/JN/	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08	<input type="checkbox"/>
/JN/	B3	EP 0 801 067	10/15/1997	EPO	C07D	453/02	<input type="checkbox"/>
/JN/	B4	GB 940,540	10/30/1963	UK	C07C		<input type="checkbox"/>
/JN/	B5	JP 135958/1994	5/17/1994	Japan	C07D	333/16	<input type="checkbox"/>
/JN/	B6	JP 92921/1994	4/5/1994	Japan	C07C	237/20	<input type="checkbox"/>
/JN/	B7	WO 91/09013	6/27/1991	PCT	C07D	207/08	<input type="checkbox"/>
/JN/	B8	WO 93/16018	8/19/1993	PCT	C05F	17/02	<input type="checkbox"/>
/JN/	B9	WO 93/16048	8/19/1993	PCT	C07D	211/26	<input type="checkbox"/>
/JN/	B10	WO 96/33973	10/31/1996	PCT	C07D	211/46	<input type="checkbox"/>
/JN/	B11	WO 97/45414	12/4/1997	PCT	C07D	211/58	<input type="checkbox"/>
/JN/	B12	WO 98/05641	2/12/1998	PCT	C07D	211/46	<input type="checkbox"/>
/JN/	B13	WO 98/29402	7/9/1998	PCT	C07D	311/20	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/JN/	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986)					

EXAMINER	/Jason Nolan/		DATE CONSIDERED	06/21/2007
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>				

INFORMATION DISCLOSURE CITATION <div style="text-align: right; font-size: small; margin-top: -10px;">  FEB 12 2007 PCT/US </div>	Docket No.: RLL-290US	Serial No.: 10/552,502
	Applicants: MEHTA <i>et al.</i>	
	Filed: 10/7/2005	Group: Art Unit 1626

 /JN/	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987)
/JN/	C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , 3:426-432 (1999)
/JN/	C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001)
/JN/	C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000)
/JN/	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , 6:142-193 (2001)
/JN/	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , 22(5):215-219 (2001)
/JN/	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , 41:691-721 (2001)
/JN/	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282
/JN/	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , 55(Suppl. 5A):33-46 (2000)
/JN/	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
/JN/	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45:984-987 (2002)
/JN/	C13	Mitsuya et al, "A Potent, Long-Active, Orally Active (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: A Novel Muscarinic M ₃ Receptor Antagonist with High Selectivity for M ₃ over M ₂ Receptors", <i>Journal of Medicinal Chemistry</i> , 43(26):5017-5029 (2000)
/JN/	C14	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , 64(25):2351-2358 (1999)
/JN/	C15	Cheng and Prusoff, "Relationship between the inhibition constant (K ₁) and the concentration of inhibitor which causes 50 per cent inhibition (I ₅₀) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973)

EXAMINER	/Jason Nolan/	DATE CONSIDERED
06/21/2007		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>		